NCT04724460CompletedPhase 4
Optimal Duration of Anticoagulation Therapy for Low-risk Pulmonary Embolism Patients With Cancer
Source: ClinicalTrials.gov · Last updated 11 Mar 2025
Brief summary (registry, in English)
The primary purpose of this study is to determine the optimal duration of anticoagulation therapy (6 months versus 18 months) with direct oral anticoagulant (DOAC) for cancer-associated low-risk pulmonary embolism patients. The major secondary purpose of this study is to investigate whether home treatment of cancer-associated low-risk pulmonary embolism patients with rivaroxaban is feasible, effective, and safe through an observational management study.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 179 (actual)
- First submitted
- 22 Jan 2021
- Start date
- 18 Feb 2021
- Primary completion date
- 27 Sept 2024
- Lead sponsor
- Takeshi Morimoto
- NCT number
- NCT04724460
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 179
- From 18 Feb 2021 to the primary completion date, 27 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindicated patients for rivaroxaban (Clinically significant liver disease, Bacterial endocarditis, Active bleeding, Inadequate contraceptive measures if of childbearing potential, Concomitant use of strong cytochrome P-450 3A4 inhibitors or inducers or P-glycoprotein inhibitors or inducers)
Other illness
- Patients who judged to be inappropriate for enrolment by the physician (including patients at a high risk of gastrointestinal or genitourinary bleeding)
Other
- Expected life expectancy \<6 months
- Patients who do not provide written informed consent
Who the study is looking for
- Patients with active cancer (solid and hematologic malignancies) presenting with objectively newly confirmed pulmonary embolism who are scheduled to be treated by anticoagulation therapy.
- Patients with an simplified Pulmonary Embolism Severity Index (PESI) score of 1 or less
Age in the registry: 20 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine Coordinator of this site? Confirm its status | Kyoto | Japan | Unknown status |
Related publications
- A Bleeding Risk Score for Cancer-Associated Venous Thromboembolism in Patients Receiving Direct Oral Anticoagulants.JACC CardioOncol · 2026 · PMID 42307155
This page is information, not medical advice. Discuss any trial with your doctor.